Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why
01:01pm, Monday, 12'th Jan 2026
Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
02:46pm, Monday, 05'th Jan 2026
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
Nello Mainolfi Sells 30,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
04:27am, Friday, 02'nd Jan 2026
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction on Wednesday, December 31st. The stock was sold at an average
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks
11:35am, Thursday, 01'st Jan 2026
Insider buying can be one of the cleanest “follow-the-money” signals in the market. Over the past month or so, three names have stood out for $100 million-plus buying tied to prominent funds and w
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
08:45am, Wednesday, 17'th Dec 2025
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi
07:38am, Monday, 15'th Dec 2025
Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
China Universal Asset Management Co. Ltd. Purchases 10,052 Shares of Kymera Therapeutics, Inc. $KYMR
05:34am, Monday, 15'th Dec 2025
China Universal Asset Management Co. Ltd. lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 77.2% in the second quarter, according to the company in its most recent disclosu
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
05:35pm, Friday, 12'th Dec 2025
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending
Kymera's Eczema Drug Gets Fast Track Designation in the United States
11:30am, Friday, 12'th Dec 2025
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
First Look: Lululemon shake-up, Broadcom AI jitters, Costco beat
07:38am, Friday, 12'th Dec 2025
Stock News Lululemon leadership change lifts shares: Lululemon Athletica (LULU) said CEO Calvin McDonald will step down Jan. 31, with CFO Meghan Frank and CCO A
Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR
04:12am, Friday, 12'th Dec 2025
Frontier Capital Management Co. LLC grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 272.7% during the undefined quarter, according to the company in its most recent 13F filing
Market Today: Fed Cut, Oracle Slide, Broadcom AI Surge
05:35pm, Thursday, 11'th Dec 2025
Stock News Oracle sinks, ripples across AI trade: Oracle (ORCL) fell about 11% after a revenue miss and heavier AI capex drove negative free cash flow, pressuri
WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
11:30pm, Tuesday, 09'th Dec 2025
WATERTOWN, Mass. , Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
11:46am, Tuesday, 09'th Dec 2025
Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
